BEAMBeam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead. | ||
 Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Scribe’s Genetic Editing Aims to Prevent Heart Attacks Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic. | ||
 Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? Beam Therapeutics' growing pipeline could reward patient investors. | ||
 Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam. Stranahan forecasted a target price of $47, […] | IInsider Monkey | |
 Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […] | IInsider Monkey | |
IInsider Monkey | ||